
Join to view full profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 855-557-0555
Fax+1 206-606-1025
Dr. Till is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002
Certifications & Licensure
WA State Medical License 2005 - 2027
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2012 Aug 09
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2017 Nov 27
Roles: Principal Investigator
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
Publications & Presentations
PubMed
- CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia.Mazyar Shadman, Mary W Redman, Sang Yun Lee, Kelsey K Baker, Dong Hoon Lee
Blood. 2026-11-05 - Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.Xiancheng Wu, Mazyar Shadman, Jenna Voutsinas, Daniel S Hippe, Timothy W Randolph
Blood Advances. 2026-09-22 - Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.Ryan C Lynch, Christina Poh, Mazyar Shadman, Brian G Till, Mengyang Di
Journal of Clinical Oncology. 2026-09-20
Abstracts/Posters
- Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomasBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical OutcomesBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Grant Support
- Mechanisms of treatment failure in chimeric antigen receptor T cell therapyFRED HUTCHINSON CANCER CENTER2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: